REPRISE trial presented as a late breaking abstract at American Society of Nephrology (ASN) Kidney Week 2017

TOKYO, JAPAN

November 4, 2017

Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced detailed results from the Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). Trial results showed that tolvaptan showed greater reduction on the primary endpoint, the rate of change in estimated glomerular filtration rate (eGFR) compared to placebo.

Health Canada issues a Notice of Compliance for ABILIFY MAINTENA, approving a new indication for the maintenance monotherapy treatment of bipolar I disorder in adult patients.

Montreal, Quebec

November 2, 2017

Otsuka Canada Pharmaceutical Inc. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for ABILIFY MAINTENA (aripiprazole for prolonged release injectable suspension), approving a new indication for the maintenance monotherapy treatment of bipolar I disorder in adult patients.

Health Canada Approves Otsuka and Lundbeck’s REXULTI™ (brexpiprazole) as a Treatment for Schizophrenia in Adults

Montreal, Quebec

February 16, 2017

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI™ (brexpiprazole) for the treatment of schizophrenia in adults. REXULTI™ was discovered by Otsuka and co-developed with Lundbeck. It will be co-marketed by the two companies and is expected to become commercially available in Canada this spring.

Now Available in Canada: First-ever treatment for adults living with a life-threatening kidney disease (ADPKD)

Montreal, Quebec

June 5, 2015